8-Methylimidazo[1,2-a]pyridine-3-sulfonyl chloride

Catalog No.: 
ACYDLE338
CAS No.: 
1781865-35-7
Molecular Formula: 
C8H7ClN2O2S
Molecular Weight: 
230.68
8-Methylimidazo[1,2-a]pyridine-3-sulfonyl chloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%
1g95%
5g95%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name8-Methylimidazo[1,2-a]pyridine-3-sulfonyl chloride
IUPAC Name8-methylimidazo[1,2-a]pyridine-3-sulfonyl chloride
MDL No.MFCD28638054
Molecular FormulaC8H7ClN2O2S
Molecular Weight230.68
SMILESO=S(C1=CN=C2C(C)=CC=CN21)(Cl)=O
InChI KeyWFNJSPBBORSZDU-UHFFFAOYSA-N
SynonymImidazo[1,2-a]pyridine-3-sulfonyl chloride, 8-methyl-
CAS No.1781865-35-7

Safety Data

Pictogram
Corrosive
Signal Word
Gefahr
Hazard Statement(s)
H290-H314
Precautionary Statement(s)
P234-P260-P264-P280-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P363-P390-P405-P406-P501

Synthetic Route by SureRoute

1. ACYDLE338 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRLNV471 route compound structure diagram
    ACRLNV471866135-66-2In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYDLE338 route product structure diagram
    ACYDLE3381781865-35-7
Inquiry

2. ACYDLE338 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRLNV471 route compound structure diagram
    ACRLNV471866135-66-2In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYDLE338 route product structure diagram
    ACYDLE3381781865-35-7
Inquiry

3. ACYDLE338 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYDLE338 route product structure diagram
    ACYDLE3381781865-35-7
Inquiry

Comments (0)